Amgen Announces Top-Line Results of Vectibix panitumumab Phase...

in patients who had not received chemotherapy before, patients lived for longer without their disease getting worse when they received Erbitux in addition to chemotherapy including irinotecan (9.9 months compared with 8.7 months, on average). In ...

The most frequent adverse reactions seen in patients with carcinomas of the head and neck receiving ERBITUX in combination with radiation therapy (n=208) versus radiation alone (n=212) (incidence "50%) were acneiform rash (87% vs 10%), radiation ...

Patients with colorectal cancer that had metastasized to the liver had improved surgical outcomes and greater survival if cetuximab (Erbitux) was added to their chemotherapy regimen. Toxicities were similar in the two groups and were mostly mild. An ...

NEW YORK Molecular Diagnostics in Cancer Testing Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular ...

Australian drug development company Alchemia Limited (ASX: ACL) today anounced the following updates regarding its marketed anticoagulant, fondaparinux; subsidary, Audeo's, HyACT platform; as well as its internal VAST drug discovery platform.

BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This ...

Alchemia's Chief Executive Officer Charles Walker and Chief Scientific Officer Tracey Brown will update investors and interested parties regarding today's announcement 22 May 2013 Alchemia Limited Company Update • $2.35M fondaparinux profit share ...

Filed under: Investing They compete in the diabetes market. The same holds true for the cardiovascular, neuroscience, oncology, and osteoporosis markets. Their animal health units go head to head. You might even say that Eli Lilly and Merck are ...

Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance. A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) ...